Clinical Trials
65 trialsBrentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
RADAR
University College, London
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
M.D. Anderson Cancer Center
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Takeda
MK-3475-667
Merck Sharp & Dohme LLC
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
National Medical Research Radiological Centre of the Ministry of Health of Russia
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Takeda
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Fondazione Italiana Linfomi - ETS
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
City of Hope Medical Center
HL-Russia-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
University College, London
EuroNetLP1
Martin-Luther-Universität Halle-Wittenberg
CheckMate 205
Bristol-Myers Squibb
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
St. Jude Children's Research Hospital
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Northwestern University
BREACH
The Lymphoma Academic Research Organisation
Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
SWOG Cancer Research Network
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
National Institute of Allergy and Infectious Diseases (NIAID)
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
Fondazione Michelangelo
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
Stanford University
Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease
Canadian Cancer Trials Group
HD17 for Intermediate Stage Hodgkin Lymphoma
University of Cologne
Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma
Martin-Luther-Universität Halle-Wittenberg
(Optimist)
King Abdullah International Medical Research Center
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Stanford University
AVD-Rev
University of Cologne
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Massachusetts General Hospital
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
Newcastle-upon-Tyne Hospitals NHS Trust
SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease
SWOG Cancer Research Network
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
Memorial Sloan Kettering Cancer Center
PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma
University of Cologne